biostudies-literatureKanbay MTravere TherapeuticsNCATS NIH HHSNIDDK NIH HHSDoris Duke Charitable FoundationSteno Diabetes Center Copenhagen (SDCC)NHLBI NIH HHSNIMHD NIH HHSBayerNational Institutes of HealthCenters for Disease ControlNIH HHS671-678https://www.ebi.ac.uk/biostudies/studies/S-EPMC11997758biostudies-literatureUnknown40(4)<h4>Background</h4>Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel anti-diabetic medications with potential beneficial effects on cardiovascular and renal outcomes, metabolic parameters and body weight. In addition to the beneficial effects on renal function, including estimated glomerular filtration rate and reduction in proteinuria, recent studies have investigated the potential role of SGLT2 inhibitor (SGLT2i) therapy on nephrolithiasis development. Nephrolithiasis, a condition affecting almost 10% of the general population at least once during a lifetime, is a common disorder with considerable risk for acute and chronic kidney injury and relatively few effective therapeutic options.<h4>Methods</h4>We performed a literature search through multiple databases, including PubMeNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationSGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.PMC11997758U54 DK083912OT2HL16184775D301-23-C-18264U54DK083912UL1 TR002319U01DK100846U01 DK100846UM1AI109568OT2 OD032581R01 MD014712U2CDK114886SDCC 3.A ComplicationsOT2 HL161847U24 DK114886R01MD014712OT2OD032581UL1TR00231975D301-21-P-12254Burlacu AKanbay MRossing PBrinza CCopur SSekreter OTuttle KRCovic AfalseSGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.<h4>Background</h4>Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel anti-diabetic medications with potential beneficial effects on cardiovascular and renal outcomes, metabolic parameters and body weight. In addition to the beneficial effects on renal function, including estimated glomerular filtration rate and reduction in proteinuria, recent studies have investigated the potential role of SGLT2 inhibitor (SGLT2i) therapy on nephrolithiasis development. Nephrolithiasis, a condition affecting almost 10% of the general population at least once during a lifetime, is a common disorder with considerable risk for acute and chronic kidney injury and relatively few effective therapeutic options.<h4>Methods</h4>We performed a literature search through multiple databases, including PubMe2025-01-01T00:00:00Z2025 Apr2026-04-07T13:20:21.325Z2026-04-07T13:17:38.148ZS-EPMC119977583911327410.1093/ndt/gfae179